Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? a randomised controlled trial.



Eldabe, Sam, Duarte, Rui V, Gulve, Ashish, Thomson, Simon, Baranidharan, Ganesan, Houten, Rachel ORCID: 0000-0002-4315-7732, Jowett, Susan, Sandhu, Harbinder, Chadwick, Raymond, Brookes, Morag
et al (show 7 more authors) (2020) Does a screening trial for spinal cord stimulation in patients with chronic pain of neuropathic origin have clinical utility and cost-effectiveness (TRIAL-STIM)? a randomised controlled trial. Pain.

[img] Text
Does_a_screening_trial_for_spinal_cord_stimulation.98362.pdf - Accepted Version
Access to this file is embargoed until 29 June 2021.

Download (1MB)

Abstract

Spinal cord stimulation (SCS) is an established treatment of chronic neuropathic pain. Although a temporary SCS screening trial is widely used to determine whether a patient should receive permanent SCS implant, its evidence base is limited. We aimed to establish the clinical utility, diagnostic accuracy, and cost-effectiveness of an SCS screening trial. A multicentre single-blind, parallel two-group randomised controlled superiority trial was undertaken at three centres in United Kingdom. Patients were randomised 1:1 to either SCS screening trial strategy (TG) or no trial screening strategy (NTG). Treatment was open label, but outcome assessors were masked. The primary outcome measure was numerical rating scale (NRS) pain at six-months follow-up. Between June 2017 and September 2018, 105 participants were enrolled and randomised (TG=54, NTG=51). Mean NRS pain decreased from 7.47 at baseline (before SCS implantation) to 4.28 at 6-months in TG and from 7.54 to 4.49 in NTG (mean group difference: 0.2, 95% CI: -1.2 to 0.9, p=0.89). We found no difference between TG and NTG in the proportion of pain responders or other secondary outcomes. SCS screening trial had a sensitivity of 100% (95% CI: 78 to 100) and specificity of 8% (95% CI: 1 to 25). The mean incremental cost-effectiveness ratio of TG versus NTG was £78,895 per additional quality-adjusted life-year (QALY) gained. In conclusion, although the SCS screening trial may have some diagnostic utility, there was no evidence that an SCS screening trial strategy provides superior patient outcomes or is cost-effective compared to a no trial screening approach.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 04 Aug 2020 08:56
Last Modified: 21 Jan 2021 08:10
DOI: 10.1097/j.pain.0000000000001977
URI: https://livrepository.liverpool.ac.uk/id/eprint/3096208